|Awarded On||August 19, 2020|
|Title||Image-guided Surgical Detection of Metastatic Disease to the Peritoneum, Lymph Nodes and Pleural Surfaces|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Ravi Srinivasan|
|Cancer Sites||All Sites|
*Pending contract negotiation
OncoNano Medicine, Inc., a spinout of UT Southwestern headquartered in Southlake, TX, developed its first product, ONM-100, for imaging cancer with the help of a $6 million CPRIT NEWCO award in 2014. ONM-100 was granted a Fast Track designation and is currently in Phase 2 trials. These initial clinical trials continue to successfully demonstrate the use of ONM-100 in imaging cancer tumors. OncoNano has discovered that ONM-100 can also be used to image and stage metastatic disease in the peritoneum, lymph nodes and pleura resulting from gastric, colorectal, prostate, ovarian, lung, and breast cancers. This important and valuable advance meets a critical unmet need for cancer patients. Today, ...